Propafenone

Generic Name
Propafenone
Brand Names
Rythmol
Drug Type
Small Molecule
Chemical Formula
C21H27NO3
CAS Number
54063-53-5
Unique Ingredient Identifier
68IQX3T69U
Background

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

Indication

Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.

Associated Conditions
Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF), Paroxysmal Supraventricular Tachycardia (PSVT), Ventricular Arrhythmia
Associated Therapies
-
Clinical Trials
Related News

Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.

Phase 4
Recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Antazoline
Drug: Propafenone
First Posted Date
2023-02-09
Last Posted Date
2023-02-14
Lead Sponsor
Centre of Postgraduate Medical Education
Target Recruit Count
105
Registration Number
NCT05720572
Locations
🇵🇱

Postgraduate Medical School, Warsaw, Poland

Bioequivalence Study of Two Formulations of Propafenone 300 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions

Phase 1
Completed
Conditions
Bioequivalence
Interventions
Drug: Propafenone
Drug: Rytmonorm
First Posted Date
2019-04-16
Last Posted Date
2019-06-06
Lead Sponsor
Pharmtechnology LLC
Target Recruit Count
32
Registration Number
NCT03915340
Locations
🇨🇦

Altasciences Company Inc., Mount-Royal, Quebec, Canada

Efficacy and Safety of Sotalol in Children With Arrhythmia

First Posted Date
2019-03-29
Last Posted Date
2019-03-29
Lead Sponsor
Shengjing Hospital
Target Recruit Count
500
Registration Number
NCT03895411
Locations
🇨🇳

Shenjing Hospital, Shenyang, Liaoning, China

Propafenone in the Treatment of Atrial Fibrillation

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Propafenone
First Posted Date
2018-09-17
Last Posted Date
2021-09-23
Lead Sponsor
TSH Biopharm Corporation Limited
Target Recruit Count
71
Registration Number
NCT03674658
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

Beta-blocker vs. Ic Antiarrhythmic Drug for PVC

Not Applicable
Withdrawn
Conditions
Premature Ventricular Complex
Interventions
Drug: Propafenone
Drug: Indenol
First Posted Date
2018-06-19
Last Posted Date
2024-04-23
Lead Sponsor
Yong Seog Oh
Registration Number
NCT03561935
Locations
🇰🇷

Seoul St Mary's Hospital, Seoul, Seo Ch-gu, Korea, Republic of

Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation

First Posted Date
2015-12-17
Last Posted Date
2019-01-28
Lead Sponsor
Yonsei University
Target Recruit Count
200
Registration Number
NCT02633774
Locations
🇰🇷

Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)

First Posted Date
2014-11-19
Last Posted Date
2017-05-09
Lead Sponsor
Uppsala University Hospital
Target Recruit Count
152
Registration Number
NCT02294955
Locations
🇸🇪

Carina Blomström Lundqvist, Uppsala, Sweden

Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

First Posted Date
2014-05-23
Last Posted Date
2014-05-23
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
600
Registration Number
NCT02145546
Locations
🇨🇳

Xinhua Hospital, Shanghai Jiao Tong University School of Medicne, Shanghai, Shanghai, China

Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Propafenone
Drug: Dronedarone
First Posted Date
2013-11-25
Last Posted Date
2013-11-25
Lead Sponsor
Samsung Medical Center
Target Recruit Count
98
Registration Number
NCT01991119
Locations
🇰🇷

Cardiac and Vascular Center, Seoul, Korea, Republic of

Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites

Phase 1
Completed
Conditions
Arrhythmia, Cardiac
Interventions
Drug: Propafenone
First Posted Date
2013-10-08
Last Posted Date
2017-06-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
38
Registration Number
NCT01956487
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy